로딩 중…
지수 로딩 중…
EyePoint Pharmaceuticals, Inc.
EYPT· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$12.42+1.39%
2026-08-03
Financials
Valuation Metrics
EyePoint Pharmaceuticals, Inc.'s Market Cap is $1.04B. At end of 2025 it was $1.52B. Ranked #2476 of 3,112 in US market (top 80%), #1013 of 1,445 on NASDAQ (top 70%), #190 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 71%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.04B | US#2,476/3,112 Sec#190/269 |
| Revenue | $8M | US#2,928/3,112 Sec#184/269 |
| Net Income | $-272M | US—/3,112 Sec—/269 |
| Total Assets | $288M | US#2,906/3,112 Sec#216/269 |
| Net Assets | $230M | US#2,682/3,112 Sec#185/269 |
| Value | ||
| P/B | 4.52x | US#2,084/3,112 Sec#130/269 |
| P/S | 136.74x | US#2,918/3,112 Sec#185/269 |
| FCF Yield | -26.08% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -117.84% | US#2,869/3,112 Sec#225/269 |
| ROA | -94.23% | US#3,043/3,112 Sec#262/269 |
| Op. Margin | -3700.89% | US#2,944/3,112 Sec#187/269 |
| Revenue Growth | -97.15% | US#2,940/3,112 Sec#186/269 |
| Financial Health | ||
| Debt Ratio | 25.06% | US#276/3,112 Sec#89/269 |
| Total Debt | $20M | US#2,701/3,112 Sec#181/269 |
| FCF | $-272M | US#2,769/3,112 Sec#232/269 |
| Cash | $78M | US#2,354/3,112 Sec#193/269 |
| Current Ratio | 6.66x | US#361/3,112 Sec#117/269 |
| Performance | ||
| 1Y Return | 27.91% | US#1,371/3,112 Sec#157/269 |
| 1M Return | -11.16% | US#2,662/3,112 Sec#175/269 |
| From 52W High | -35.01% | US#2,362/3,112 Sec#180/269 |
| 1Y MDD | -39.26% | US#1,914/3,112 Sec#141/269 |
| Trading | ||
| Volume | 1,458,769 shares | US#1,143/3,112 Sec#107/269 |
| Trading Value | $18M | US#2,027/3,112 Sec#154/269 |
| Per Share | ||
| EPS | $-2.79 | US—/3,112 Sec—/269 |
| BPS | $3.69 | US#2,345/3,112 Sec#151/269 |